Lonza to expand manufacturing drug substance for COVID-19 Vaccine Moderna
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
Aurobindo has one of the most enduring generics ecosystems among peers
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
Subscribe To Our Newsletter & Stay Updated